In 2021, vaccine giant Merca East opened its year with a cold splash of cold water on the development of a "crazy" new crown vaccine. January 25th, Mercedon will stop developing two candidate vaccines V590 and V591 for SARS-CoV-2/COVID-19.
New drug for mild asthma! AstraZeneta has been approved ® the ® Drug Administration to treat mild asthma in adults and adolescents over 12 years of age!
Time of Update: 2021-03-04
are not timely and accurate diagnosis and treatment. , up to 30 to 40 percent of people with mild asthma are likely to have severe acute seizures. to effectively control symptoms and reduce the risk of acute onset, early anti-inflammatory
A screen to identify drug resistant variants to target-directed anti-cancer agents
Time of Update: 2021-03-04
Using imatinib and BCR/ABL as a paradigm for a drug-target pair, we recently reported a retroviral vector-based screening strategy to identify the spectrum of resistance-conferring mutations.
The second batch of volume purchase lists flowed out of generic drugs to kill prices or more violently
Time of Update: 2021-03-04
/> As a result of this news, on November 29th, the share prices of Stone Pharmaceutical Group, Green Leaf Pharmaceuticals, Hengrui Pharmaceuticals and other related pharmaceutical companies fell sharply. "From the current information
First lupus nephritis (LN) oral drug! Lupkynis, the best-in-class calcium-adjusted neurophosphatase inhibitor, has been approved by the FDA!
Time of Update: 2021-03-04
recently, the company announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin), a joint background immunosuppressive therapy for the treatment of active lupus nephritis (LN) adult patients.
quarters of the new drug sales revenue of 9.5 billion yuan
Time of Update: 2021-03-04
the first three quarters of 2019, Shi Pharmaceutical Group's pharmaceutical business maintained strong growth, with sales revenue of RMB13,387 million, up 35.1% YoY, according to the company's financial results.
Chinese scientists have found the mechanism of "plant killer" chamomile
Time of Update: 2021-03-04
, Jan. 27 (Xinhua) -- A study conducted by the China Agriculture Shenzhen Agricultural Genomics Research Institute has been published online in the academic journal Nature Communications. This study reveals the environmental adaptive
A batch of ointments was exposed to strictly check the sale of non-drugs in pharmacies
Time of Update: 2021-03-04
It is reported that the Gusu District Market Supervision Bureau, after receiving the inspection recommendations, for retail pharmacies to carry out a special rectification activities.
by flowering plants
Time of Update: 2021-03-04
The paper announced the high-quality genome of the Blue Star water lily and analyzed it, taking a crucial step in solving the mystery of how flowering plants can quickly take over the Earth in 200 million years.
Generic drugs will accelerate the replacement of the original research drug high-quality generic drug companies to benefit
Time of Update: 2021-03-04
According to the Economic Observer Network reported, recently, the State Information Center, China Economic Information Network released the "2019 Pharmaceutical Industry Development Report - Outlook: strict control of fees, drug prices, innovative
The shortage of cheap drugs has eased this year
Time of Update: 2021-03-04
situation, patients have to spend nearly 100 yuan to buy 25 tablets / bottle of imported drugs. At the end of April, the Beijing Municipal Drug Administration disclosed that the relevant departments and pharmacies have coordinated
K drug small cell lung cancer PHASE III clinical reach PFS endpoint miss OS endpoint
Time of Update: 2021-03-03
results. The results showed that the Keytruda chemotherapy combination achieved a significant increase in the primary endpoint of patients' progress-free survival (PFS) (HR=0.75,95% CI, 0.61-0.91), but missed the primary endpoint of total lifetime (OS
The late trial of migraine drugs was successful
Time of Update: 2021-03-03
Axsome's share increased by more than 80 percent last month after the Phase III study of the experimental drug AXS-05 in adults with moderate to severe depression reached its primary endpoint.
